UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance
Aktuelle Themen und perspektiven für eine gesundheitsfördernde stadtentwicklungWeltweit nimmt die Urbanisierung zu: Inzwischen lebt mehr als die Hälfte der Weltbevölkerung in Städten, in Europa sind es deutlich mehr als 70% der Bevölkerung (WHO, 2010a). Aufgrund die...ser Entwicklung hat sich »Urban Health« als neues Forschungsfeld etabliert, in dem der Einfluss der städtischen Umwelt auf die Gesundheit unter-sucht wird (Vlahov & Galea, 2003; Galea & Vlahov, 2005a; Heaton et al., 2010; Braür & Hystad, 2014).
more
Compared to the previous five-year assessment period 2011–2015, the current five-year period 2015–2019 has seen a continued increase in carbon dioxide (CO2 ) emissions and an accelerated increase in the atmospheric concentration of major greenhouse gases (GHGs), with growth rates nearly 20% high...er. The increase in the oceanic CO2 concentration has increased the ocean’s acidity.
The five-year period 2015–20191 is likely to be the warmest of any equivalent period on record globally, with a 1.1 °C global temperature increase since the pre-industrial period and a 0.2 °C increase compared to the previous five-year period.
more
Report on ILGA-Europe/COC fact-finding mission
Bishkek 2015
Accessed: 26.09.2019
Mission report April 2016
braz j infect dis 2 0 1 7;2 1(2):162–170
http://dx.doi.org/10.1016/j.bjid.2016.11.006
1413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
July 2019
Policy brief
HIV Treatment
HIV Treatment - Interim Guidance
Findings from the People Living with HIV Stigma Index
Procurement and supply management activities are fundamental to consistent and reliable access to essential medicines and health products. To reduce the impact of CVD, action needs to be taken to improve prevention, diagnosis, care and management of CVD diseases. Affordable essential medicines and t...echnologies to manage CVD disease must be available where and when they are required. Medicines and technologies need to be managed appropriately to ensure that the correct medicines are selected, procured in the right quantities, distributed to facilities in a timely manner, and handled and stored in a way that maintains their quality. This needs to be backed up by policies that enable sufficient quantities to be procured in order to reduce cost inefficiencies, ensure the reliability and security of the distribution system, and encourage the appropriate use of these health products. In order to avoid stock-outs and the disruption of treatment, all related activities need to be conducted in a timely manner, with performance continually monitored, and prompt action taken in response to problems that may arise. Additionally, medication must be dispensed correctly and used rationally by the healthcare provider and patient alike. The purpose of this guide is to explain the necessary steps.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03